Bortezomib

VELCADE®

Overview

Bortezomib is used to treat multiple myeloma and mantle cell lymphoma. It is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Bortezomib is given as an injection under the skin (subcutaneously) or injected into a vein through an IV.

SparkCures ID 1
Developed By Takeda Oncology
Brand Name Velcade®
Generic Name Bortezomib
Treatment Classifications

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

SparkCures Verified Accurate, up-to-date information. Learn more


Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

SparkCures Verified Accurate, up-to-date information. Learn more


Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

SparkCures Verified Accurate, up-to-date information. Learn more


Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources

There are no resources, links or videos to display for this treatment.